Nature Communications (Feb 2019)

Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

  • Li-Ming Gan,
  • Maria Lagerström-Fermér,
  • Leif G. Carlsson,
  • Cecilia Arfvidsson,
  • Ann-Charlotte Egnell,
  • Anna Rudvik,
  • Magnus Kjaer,
  • Anna Collén,
  • James D. Thompson,
  • John Joyal,
  • Ligia Chialda,
  • Thomas Koernicke,
  • Rainard Fuhr,
  • Kenneth R. Chien,
  • Regina Fritsche-Danielson

DOI
https://doi.org/10.1038/s41467-019-08852-4
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 9

Abstract

Read online

Chemically modified mRNA is a new approach for therapeutic protein expression that could be applied to angiogenesis. Here the authors show in a phase 1 clinical trial that a modified mRNA encoding VEGF-A is well tolerated in patients with type 2 diabetes.